ZNF77 and myotonic dystrophy type 1: By using 414C2 (healthy control), Pt-1 (DM1 patient) and Pt-1ΔCTG (genome-edited) iPSC lines, we first assessed the myogenic differentiation efficiency by immunocytochemistry for MyHC.